Apolipoprotein Mimetic Peptides as Modulators of Lipoprotein Function

Area of Science:

• Biochemistry
• Cardiovascular Research
• Drug Discovery

Background:

• Apolipoprotein A-I (apoA-I) and apolipoprotein E (apoE) are key proteins with anti-atherogenic properties.
• Both proteins feature amphipathic helical structures essential for lipid solubilization.
• ApoA-I has class A helices, while apoE includes a receptor-binding domain.

Purpose of the Study:

• To review the development of apolipoprotein mimetic peptides.
• To highlight peptides designed to mimic apoA-I and apoE functions.
• To discuss their progression into human clinical trials.

Main Methods:

• Design of an 18-residue peptide (18A) to mimic apoA-I's amphipathic helices.
• Synthesis of a hybrid peptide (Ac-hE18A-NH2) linking the apoA-I mimetic to apoE's receptor-binding domain.
• Administration of peptides in animal models of atherosclerosis and dyslipidemia.

Main Results:

• ApoA-I mimetic peptides inhibited lesion formation without altering plasma cholesterol.
• ApoE mimetic peptides significantly reduced plasma cholesterol and lesion development.
• These findings established the field of apolipoprotein mimetic peptides.

Conclusions:

• Apolipoprotein mimetic peptides represent a novel therapeutic strategy for atherosclerosis.
• Both apoA-I and apoE mimetics have demonstrated efficacy in preclinical models.
• The field has advanced to human clinical trials for these peptide-based therapies.